Pasithea publishes investor presentation on PAS-004 macrocyclic MEK inhibitor program in NF1 and solid tumors
KTTA•NF1 focus and expected timing
Initial focus is adult NF1 plexiform neurofibromas, followed by NF1 cutaneous neurofibromas; interim adult NF1-PN results are expected in 2H 2026.
PAS-004 development plans and interim Phase 1 data
Pasithea outlined clinical development plans for PAS-004, a macrocyclic MEK1/2 inhibitor targeting NF1 and MAPK pathway-driven solid tumors.
Interim Phase 1 monotherapy data in advanced cancers showed no dose-limiting toxicities; treatment-related adverse events were Grade 1-2.
Pharmacokinetics showed an approximately 60-hour half-life; cohort 7 peak and trough concentrations exceeded the cellular IC50.
One partial response was reported in a MEK-rechallenged patient with a BRAF V600E-mutated tumor; the patient remained on treatment at 11 months.
